Asia-Pacific In-Vitro Diagnostics Market 2024–2030

Plastic Optic Fiber Market Report Thumbnail

Asia-Pacific In-Vitro Diagnostics Market by Type (Reagents, Instruments, and Software & Services), by Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Other IVD Techniques), by Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Others), and by End User (Stand Alone, Laboratory, Hospitals, Academics and Medical Schools, Point of Care Testing, and Other End Users) – Opportunity Analysis and Industry Forecast, 2024–2030

Download PDF

Speak to Our Analyst

Asia-Pacific In-Vitro Diagnostics Market Overview

The Asia-Pacific In-Vitro Diagnostics Market size was valued at USD 27.51 billion in 2023, and is predicted to reach USD 40.79 billion by 2030, at a CAGR of 5.4% from 2024 to 2030. In-vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions. IVD tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology.

These tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, IVD tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics. Also, immunoassay experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.

Increasing Chronic Disease Prevalence in Asia-Pacific Drives Significant Market Growth

The high prevalence of chronic diseases, particularly cardiovascular diseases and cancer, highlights the crucial need for immunodiagnostic tests that enable early detection and continuous monitoring. This growing demand is further amplified by substantial healthcare spending in the region, which strengthens healthcare infrastructure and increases access to diagnostic services.

Enhanced financial resources allow for the adoption of advanced diagnostic technologies, improving the ability to diagnose and manage these chronic conditions effectively. Consequently, the combination of rising chronic disease rates and increased healthcare expenditure is driving significant growth in the in-vitro diagnostic market in the Asia-Pacific region.

Technological Advancements Drive the Growth of Market in Asia-Pacific

Technological innovations by market players are significantly enhancing diagnostic capabilities, leading to the expanding Asia-Pacific in-vitro diagnostics market demand. These advancements enable more accurate, efficient, and faster diagnostic tests, which are essential for early detection and effective management of diseases.

Coupled with evolving healthcare needs and substantial investments in healthcare infrastructure, the region is witnessing a surge in demand for advanced diagnostic solutions. This creates significant growth opportunities for the in-vitro diagnostics market, as healthcare providers adopt these cutting-edge technologies to improve patient outcomes and meet the rising demand for high-quality clinical diagnostic services.

High Research, Development, and Regulatory Approval Costs Hinder the Market Growth

High costs associated with research, development, and regulatory approval are significant factors restraining the Asia-Pacific IVD market expansion. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development.

This investment often encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability. Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from market expansion.

Introduction of Point-of-Care Testing Solutions in IVD Creates Opportunity

Point-of-care testing (POCT) is poised to significantly drive the Asia-Pacific in-vitro diagnostics market demand in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings.

With POCT technologies offering rapid tests for infectious diseases, cardiac markers, glucose monitoring, pregnancy testing, and more, healthcare providers can quickly assess patients' conditions and make timely treatment decisions.

By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.

China Dominates the Asia-Pacific In-Vitro Diagnostics Market Share

The prevalence of chronic diseases significantly drives the growth of the in-vitro diagnostics market in China. According to National Institutes of Health, in China, there are higher rates of cardiovascular disease, cancer, chronic respiratory disease, and diabetes compared to regions with similar social development levels. These non-communicable diseases are responsible for 88.5% of all deaths and contribute to 84.9% of the disease burden, as measured by disability-adjusted life years (DALYs).

As these conditions continue to rise, there is an increasing demand for accurate and efficient diagnostic solutions to effectively manage and monitor patient health. IVD tests play a crucial role in this landscape by enabling early disease detection, personalized treatment strategies, and ongoing disease monitoring.

Singapore to Witness Substantial Growth in the Market

Increased healthcare expenditure in Singapore serves as a significant factor for the growth of the in-vitro diagnostics market. According to World Trade Administration, the Singapore National Health Expenditure is projected to reach around USD 44 billion by 2030 to address both short and long-term infrastructure needs and to provide support for healthcare provisions and subsidies for low-income individuals. This investment creates opportunities for the adoption of advanced in-vitro diagnostics technologies, leading to improved disease detection, monitoring, and personalized treatment options.

Competitive Landscape

The promising players operating in the Asia-Pacific in-vitro diagnostics industry include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

Asia-Pacific In-Vitro Diagnostics Market Key Segments

By Type

Reagents
Instruments
Software & Services

By Technique

Immunodiagnostics
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Rapid Tests
- Chemiluminescence Immunoassay (CLIA)
- Enzyme-linked Immunosorbent spot (ELISpot)
- Radioimmunoassay (RIA)
- Western Blot
Hematology
Molecular Diagnostics
- PCR
- INAAT
- Hybridization
- DNA diagnostics
- Microarray
- Other Molecular Diagnostics
Tissue Diagnostics
Clinical Chemistry
- Basic Metabolic Panel
- Liver Panel
- Renal Profile
- Lipid Profile
- Thyroid Function Panel
- Electrolyte Panel
- Speciality Chemicals
Other IVD Techniques

By Application

Infectious Diseases
Cancer
Cardiac Diseases
Immune System Disorders
Nephrological Diseases
Gastrointestinal Diseases
Others

By End User

Stand Alone Laboratory
Hospitals
Academics and Medical Schools
Point of Care Testing
Other End Users

By Country

China
India
South Korea
Australia
Indonesia
Singapore
Taiwan
Thailand
Rest of Asia-Pacific

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Market Size Value in 2023	USD 27.51 billion
Revenue Forecast in 2030	USD 40.79 billion
Value Growth Rate	CAGR of 5.4% from 2024 to 2030
Analysis Period	2023–2030
Base Year Considered	2023
Forecast Period	2024–2030
Market Size Estimation	Billion (USD)
Growth Factors	Increasing Chronic Disease Prevalence in Asia-Pacific Drives Significant Market Growth. Technological Advancement Drives the Growth of Asia-Pacific IVD Market.
Companies Profiled	10
Countries Covered	8
Customization Scope	Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.

KEY PLAYERS

Roche Holding AG
Abbott Laboratories
Thermo Fisher Scientific Inc.
Danaher Corporation
Becton, Dickinson and Company
Siemens Healthineers AG
bioMérieux SA
Sysmex Corporation
QIAGEN N.V.
Bio-Rad Laboratories, Inc.

1 INTRODUCTION

1.1 REPORT DESCRIPTION

1.2 RESEARCH METHODOLOGY

1.2.1 SECONDARY RESEARCH

1.2.2 DATA ANALYSIS FRAMEWORK

1.2.3 MARKET SIZE ESTIMATION

1.2.4 FORECASTING

1.2.5 PRIMARY RESEARCH AND DATA VALIDATION

2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET – EXECUTIVE SUMMARY

2.1. MARKET SNAPSHOT, 2023 - 2030, MILLION USD

3 PORTER’S FIVE FORCE MODEL ANALYSIS

3.1 BARGAINING POWER OF SUPPLIERS

3.2 BARGAINING POWER OF BUYERS

3.3 DEGREE OF COMPETITION

3.4 THREAT OF SUBSTITUTE

3.5 THREAT OF NEW ENTRANTS

4 MARKET SHARE ANALYSIS

4.1 MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2023

5 MARKET DYNAMICS

5.1 GROWTH DRIVERS

5.1.1 DRIVER 1

5.1.2 DRIVER 2

5.1.3 DRIVER 3

5.1.4 DRIVER 4

5.2 CHALLENGES

5.2.1 CHALLENGE 1

5.2.2 CHALLENGE 2

5.2.3 CHALLENGE 3

5.2.4 CHALLENGE 4

5.3 OPPORTUNITIES

5.3.1 OPPORTUNITY 1

5.3.2 OPPORTUNITY 2

6 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET BY TYPE

6.1 OVERVIEW

6.2 REAGENTS

6.2.1 REAGENTS MARKET, BY COUNTRY

6.3 INSTRUMENTS

6.3.1 INSTRUMENTS MARKET, BY COUNTRY

6.4 SOFTWARE AND SERVICES

6.4.1 SOFTWARE AND SERVICES MARKET, BY COUNTRY

7 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET BY TECHNIQUE

7.1 OVERVIEW

7.2 IMMUNODIAGNOSTICS

7.2.1 IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

7.2.1.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET, BY COUNTRY

7.2.1.2 RAPID TESTS MARKET, BY COUNTRY

7.2.1.3 CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET, BY COUNTRY

7.2.1.4 ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT) MARKET, BY COUNTRY

7.2.1.5 RADIOIMMUNOASSAY (RIA) MARKET, BY COUNTRY

7.2.1.6 WESTERN BLOT MARKET, BY COUNTRY

7.2.2 IMMUNODIAGNOSTICS MARKET, BY COUNTRY

7.3 HEMATOLOGY

7.3.1 HEMATOLOGY MARKET, BY COUNTRY

7.4 MOLECULAR DIAGNOSTICS

7.4.1 MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

7.4.1.1 PCR MARKET, BY COUNTRY

7.4.1.2 INAAT MARKET, BY COUNTRY

7.4.1.3 HYBRIDIZATION MARKET, BY COUNTRY

7.4.1.4 DNA DIAGNOSTICS MARKET, BY COUNTRY

7.4.1.5 MICROARRAY MARKET, BY COUNTRY

7.4.1.6 OTHER MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY

7.4.2 MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY

7.5 TISSUE DIAGNOSTICS

7.5.1 TISSUE DIAGNOSTICS MARKET, BY COUNTRY

7.6 CLINICAL CHEMISTRY

7.6.1 CLINICAL CHEMISTRY MARKET, BY TECHNIQUE

7.6.1.1 BASIC METABOLIC PANEL MARKET, BY COUNTRY

7.6.1.2 LIVER PANEL MARKET, BY COUNTRY

7.6.1.3 RENAL PROFILE MARKET, BY COUNTRY

7.6.1.4 LIPID PROFILE MARKET, BY COUNTRY

7.6.1.5 THYROID FUNCTION PANEL MARKET, BY COUNTRY

7.6.1.6 ELECTROLYTE PANEL MARKET, BY COUNTRY

7.6.1.7 SPECIALITY CHEMICALS MARKET, BY COUNTRY

7.6.2 CLINICAL CHEMISTRY MARKET, BY COUNTRY

7.7 OTHER IVD TECHNIQUES

7.7.1 OTHER IVD TECHNIQUES MARKET, BY COUNTRY

8 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET BY APPLICATION

8.1 OVERVIEW

8.2 INFECTIOUS DISEASES

8.2.1 INFECTIOUS DISEASES MARKET, BY COUNTRY

8.3 CANCER

8.3.1 CANCER MARKET, BY COUNTRY

8.4 CARDIAC DISEASES

8.4.1 CARDIAC DISEASES MARKET, BY COUNTRY

8.5 IMMUNE SYSTEM DISORDERS

8.5.1 IMMUNE SYSTEM DISORDERS MARKET, BY COUNTRY

8.6 NEPHROLOGICAL DISEASES

8.6.1 NEPHROLOGICAL DISEASES MARKET, BY COUNTRY

8.7 GASTROINTESTINAL DISEASES

8.7.1 GASTROINTESTINAL DISEASES MARKET, BY COUNTRY

8.8 OTHERS

8.8.1 OTHERS MARKET, BY COUNTRY

9 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET BY END USER

9.1 OVERVIEW

9.2 STAND ALONE LABORATORY

9.2.1 STAND ALONE LABORATORY MARKET, BY COUNTRY

9.3 HOSPITALS

9.3.1 HOSPITALS MARKET, BY COUNTRY

9.4 ACADEMICS AND MEDICAL SCHOOLS

9.4.1 ACADEMICS AND MEDICAL SCHOOLS MARKET, BY COUNTRY

9.5 POINT OF CARE TESTING

9.5.1 POINT OF CARE TESTING MARKET, BY COUNTRY

9.6 OTHER END USERS

9.6.1 OTHER END USERS MARKET, BY COUNTRY

10 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY

10.1 OVERVIEW

10.2 AUSTRALIA

10.2.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.2.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.2.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.2.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER

10.3 CHINA

10.3.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.3.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.3.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER

10.4 INDIA

10.4.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.4.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.4.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER

10.5 JAPAN

10.5.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.5.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.5.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.5.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER

10.6 SOUTH KOREA

10.6.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.6.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.6.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.6.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER

10.7 INDONESIA

10.7.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.7.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.7.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.7.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER

10.8 SINGAPORE

10.8.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.8.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.8.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.8.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER

10.9 TAIWAN

10.9.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.9.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.9.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.9.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER

10.10 THAILAND

10.10.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.10.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.10.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.10.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER

10.11 REST OF ASIA-PACIFIC

10.11.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.11.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.11.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.11.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER

11 COMPANY PROFILES

11.1 ROCHE HOLDING AG

11.1.1 COMPANY OVERVIEW

11.1.2 COMPANY SNAPSHOT

11.1.3 OPERATING BUSINESS SEGMENTS

11.1.4 PRODUCT PORTFOLIO

11.1.5 BUSINESS PERFORMANCE

11.1.6 BUSINESS SEGMENTS

11.1.7 GEOGRAPHIC SEGMENTS

11.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.1.9 PRIMARY MARKET COMPETITORS

11.2 ABBOTT LABORATORIES

11.2.1 COMPANY OVERVIEW

11.2.2 COMPANY SNAPSHOT

11.2.3 OPERATING BUSINESS SEGMENTS

11.2.4 PRODUCT PORTFOLIO

11.2.5 BUSINESS PERFORMANCE

11.2.6 BUSINESS SEGMENTS

11.2.7 GEOGRAPHIC SEGMENTS

11.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.2.9 PRIMARY MARKET COMPETITORS

11.3 THERMO FISHER SCIENTIFIC INC.

11.3.1 COMPANY OVERVIEW

11.3.2 COMPANY SNAPSHOT

11.3.3 OPERATING BUSINESS SEGMENTS

11.3.4 PRODUCT PORTFOLIO

11.3.5 BUSINESS PERFORMANCE

11.3.6 BUSINESS SEGMENTS

11.3.7 GEOGRAPHIC SEGMENTS

11.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.3.9 PRIMARY MARKET COMPETITORS

11.4 DANAHER CORPORATION

11.4.1 COMPANY OVERVIEW

11.4.2 COMPANY SNAPSHOT

11.4.3 OPERATING BUSINESS SEGMENTS

11.4.4 PRODUCT PORTFOLIO

11.4.5 BUSINESS PERFORMANCE

11.4.6 BUSINESS SEGMENTS

11.4.7 GEOGRAPHIC SEGMENTS

11.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.4.9 PRIMARY MARKET COMPETITORS

11.5 BECTON, DICKINSON AND COMPANY

11.5.1 COMPANY OVERVIEW

11.5.2 COMPANY SNAPSHOT

11.5.3 OPERATING BUSINESS SEGMENTS

11.5.4 PRODUCT PORTFOLIO

11.5.5 BUSINESS PERFORMANCE

11.5.6 BUSINESS SEGMENTS

11.5.7 GEOGRAPHIC SEGMENTS

11.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.5.9 PRIMARY MARKET COMPETITORS

11.6 SIEMENS HEALTHINEERS AG

11.6.1 COMPANY OVERVIEW

11.6.2 COMPANY SNAPSHOT

11.6.3 OPERATING BUSINESS SEGMENTS

11.6.4 PRODUCT PORTFOLIO

11.6.5 BUSINESS PERFORMANCE

11.6.6 BUSINESS SEGMENTS

11.6.7 GEOGRAPHIC SEGMENTS

11.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.6.9 PRIMARY MARKET COMPETITORS

11.7 BIOMÉRIEUX SA

11.7.1 COMPANY OVERVIEW

11.7.2 COMPANY SNAPSHOT

11.7.3 OPERATING BUSINESS SEGMENTS

11.7.4 PRODUCT PORTFOLIO

11.7.5 BUSINESS PERFORMANCE

11.7.6 BUSINESS SEGMENTS

11.7.7 GEOGRAPHIC SEGMENTS

11.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.7.9 PRIMARY MARKET COMPETITORS

11.8 SYSMEX CORPORATION

11.8.1 COMPANY OVERVIEW

11.8.2 COMPANY SNAPSHOT

11.8.3 OPERATING BUSINESS SEGMENTS

11.8.4 PRODUCT PORTFOLIO

11.8.5 BUSINESS PERFORMANCE

11.8.6 BUSINESS SEGMENTS

11.8.7 GEOGRAPHIC SEGMENTS

11.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.8.9 PRIMARY MARKET COMPETITORS

11.9 QIAGEN N.V.

11.9.1 COMPANY OVERVIEW

11.9.2 COMPANY SNAPSHOT

11.9.3 OPERATING BUSINESS SEGMENTS

11.9.4 PRODUCT PORTFOLIO

11.9.5 BUSINESS PERFORMANCE

11.9.6 BUSINESS SEGMENTS

11.9.7 GEOGRAPHIC SEGMENTS

11.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.9.9 PRIMARY MARKET COMPETITORS

11.10 BIO-RAD LABORATORIES, INC.

11.10.1 COMPANY OVERVIEW

11.10.2 COMPANY SNAPSHOT

11.10.3 OPERATING BUSINESS SEGMENTS

11.10.4 PRODUCT PORTFOLIO

11.10.5 BUSINESS PERFORMANCE

11.10.6 BUSINESS SEGMENTS

11.10.7 GEOGRAPHIC SEGMENTS

11.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.10.9 PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)

TABLE 2. REAGENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 3. INSTRUMENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 4. SOFTWARE AND SERVICES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 5. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)

TABLE 6. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 7. RAPID TESTS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 8. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 9. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 10. RADIOIMMUNOASSAY (RIA), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 11. WESTERN BLOT, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 12. IMMUNODIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 13. HEMATOLOGY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 14. PCR, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 15. INAAT, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 16. HYBRIDIZATION, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 17. DNA DIAGNOSTICS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 18. MICROARRAY, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 19. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 20. MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 21. TISSUE DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 22. BASIC METABOLIC PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 23. LIVER PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 24. RENAL PROFILE, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 25. LIPID PROFILE, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 26. THYROID FUNCTION PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 27. ELECTROLYTE PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 28. SPECIALITY CHEMICALS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 29. CLINICAL CHEMISTRY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 30. OTHER IVD TECHNIQUES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 31. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)

TABLE 32. INFECTIOUS DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 33. CANCER, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 34. CARDIAC DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 35. IMMUNE SYSTEM DISORDERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 36. NEPHROLOGICAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 37. GASTROINTESTINAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 38. OTHERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 39. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)

TABLE 40. STAND ALONE LABORATORY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 41. HOSPITALS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 42. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 43. POINT OF CARE TESTING, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 44. OTHER END USERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 45. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 46. AUSTRALIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)

TABLE 47. AUSTRALIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)

TABLE 48. AUSTRALIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)

TABLE 49. AUSTRALIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)

TABLE 50. CHINA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)

TABLE 51. CHINA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)

TABLE 52. CHINA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)

TABLE 53. CHINA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)

TABLE 54. INDIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)

TABLE 55. INDIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)

TABLE 56. INDIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)

TABLE 57. INDIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)

TABLE 58. JAPAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)

TABLE 59. JAPAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)

TABLE 60. JAPAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)

TABLE 61. JAPAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)

TABLE 62. SOUTH KOREA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)

TABLE 63. SOUTH KOREA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)

TABLE 64. SOUTH KOREA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)

TABLE 65. SOUTH KOREA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)

TABLE 66. INDONESIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)

TABLE 67. INDONESIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)

TABLE 68. INDONESIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)

TABLE 69. INDONESIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)

TABLE 70. SINGAPORE ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)

TABLE 71. SINGAPORE ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)

TABLE 72. SINGAPORE ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)

TABLE 73. SINGAPORE ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)

TABLE 74. TAIWAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)

TABLE 75. TAIWAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)

TABLE 76. TAIWAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)

TABLE 77. TAIWAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)

TABLE 78. THAILAND ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)

TABLE 79. THAILAND ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)

TABLE 80. THAILAND ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)

TABLE 81. THAILAND ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)

TABLE 82. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)

TABLE 83. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)

TABLE 84. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)

TABLE 85. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)

TABLE 86. ROCHE HOLDING AG: COMPANY SNAPSHOT

TABLE 87. ROCHE HOLDING AG: OPERATING BUSINESS SEGMENTS

TABLE 88. ROCHE HOLDING AG: PRODUCT PORTFOLIO

TABLE 89. ROCHE HOLDING AG: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 90. ROCHE HOLDING AG: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 91. ROCHE HOLDING AG: KEY STRATERGY

TABLE 92. ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 93. ABBOTT LABORATORIES: OPERATING BUSINESS SEGMENTS

TABLE 94. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 95. ABBOTT LABORATORIES: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 96. ABBOTT LABORATORIES: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 97. ABBOTT LABORATORIES: KEY STRATERGY

TABLE 98. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT

TABLE 99. THERMO FISHER SCIENTIFIC INC.: OPERATING BUSINESS SEGMENTS

TABLE 100. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO

TABLE 101. THERMO FISHER SCIENTIFIC INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 102. THERMO FISHER SCIENTIFIC INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 103. THERMO FISHER SCIENTIFIC INC.: KEY STRATERGY

TABLE 104. DANAHER CORPORATION: COMPANY SNAPSHOT

TABLE 105. DANAHER CORPORATION: OPERATING BUSINESS SEGMENTS

TABLE 106. DANAHER CORPORATION: PRODUCT PORTFOLIO

TABLE 107. DANAHER CORPORATION: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 108. DANAHER CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 109. DANAHER CORPORATION: KEY STRATERGY

TABLE 110. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT

TABLE 111. BECTON, DICKINSON AND COMPANY: OPERATING BUSINESS SEGMENTS

TABLE 112. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO

TABLE 113. BECTON, DICKINSON AND COMPANY: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 114. BECTON, DICKINSON AND COMPANY: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 115. BECTON, DICKINSON AND COMPANY: KEY STRATERGY

TABLE 116. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT

TABLE 117. SIEMENS HEALTHINEERS AG: OPERATING BUSINESS SEGMENTS

TABLE 118. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO

TABLE 119. SIEMENS HEALTHINEERS AG: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 120. SIEMENS HEALTHINEERS AG: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 121. SIEMENS HEALTHINEERS AG: KEY STRATERGY

TABLE 122. BIOMéRIEUX SA: COMPANY SNAPSHOT

TABLE 123. BIOMéRIEUX SA: OPERATING BUSINESS SEGMENTS

TABLE 124. BIOMéRIEUX SA: PRODUCT PORTFOLIO

TABLE 125. BIOMéRIEUX SA: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 126. BIOMéRIEUX SA: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 127. BIOMéRIEUX SA: KEY STRATERGY

TABLE 128. SYSMEX CORPORATION: COMPANY SNAPSHOT

TABLE 129. SYSMEX CORPORATION: OPERATING BUSINESS SEGMENTS

TABLE 130. SYSMEX CORPORATION: PRODUCT PORTFOLIO

TABLE 131. SYSMEX CORPORATION: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 132. SYSMEX CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 133. SYSMEX CORPORATION: KEY STRATERGY

TABLE 134. QIAGEN N.V.: COMPANY SNAPSHOT

TABLE 135. QIAGEN N.V.: OPERATING BUSINESS SEGMENTS

TABLE 136. QIAGEN N.V.: PRODUCT PORTFOLIO

TABLE 137. QIAGEN N.V.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 138. QIAGEN N.V.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 139. QIAGEN N.V.: KEY STRATERGY

TABLE 140. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT

TABLE 141. BIO-RAD LABORATORIES, INC.: OPERATING BUSINESS SEGMENTS

TABLE 142. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO

TABLE 143. BIO-RAD LABORATORIES, INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 144. BIO-RAD LABORATORIES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 145. BIO-RAD LABORATORIES, INC.: KEY STRATERGY

LIST OF FIGURES

FIGURE 1. BARGAINING POWER OF SUPPLIERS

FIGURE 2. BARGAINING POWER OF BUYERS

FIGURE 3. DEGREE OF COMPETITION

FIGURE 4. THREAT OF SUBSTITUTE

FIGURE 5. THREAT OF NEW ENTRANTS

FIGURE 6. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)

FIGURE 7. REAGENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 8. INSTRUMENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 9. SOFTWARE AND SERVICES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 10. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)

FIGURE 11. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 12. RAPID TESTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 13. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 14. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 15. RADIOIMMUNOASSAY (RIA), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 16. WESTERN BLOT, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 17. IMMUNODIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 18. HEMATOLOGY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 19. PCR, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 20. INAAT, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 21. HYBRIDIZATION, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 22. DNA DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 23. MICROARRAY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 24. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 25. MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 26. TISSUE DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 27. BASIC METABOLIC PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 28. LIVER PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 29. RENAL PROFILE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 30. LIPID PROFILE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 31. THYROID FUNCTION PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 32. ELECTROLYTE PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 33. SPECIALITY CHEMICALS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 34. CLINICAL CHEMISTRY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 35. OTHER IVD TECHNIQUES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 36. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)

FIGURE 37. INFECTIOUS DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 38. CANCER, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 39. CARDIAC DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 40. IMMUNE SYSTEM DISORDERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 41. NEPHROLOGICAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 42. GASTROINTESTINAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 43. OTHERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 44. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)

FIGURE 45. STAND ALONE LABORATORY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 46. HOSPITALS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 47. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 48. POINT OF CARE TESTING, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 49. OTHER END USERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 50. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY REGION 2023-2030, (MILLION USD)

FIGURE 51. AUSTRALIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)

FIGURE 52. AUSTRALIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)

FIGURE 53. AUSTRALIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)

FIGURE 54. AUSTRALIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)

FIGURE 55. CHINA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)

FIGURE 56. CHINA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)

FIGURE 57. CHINA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)

FIGURE 58. CHINA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)

FIGURE 59. INDIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)

FIGURE 60. INDIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)

FIGURE 61. INDIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)

FIGURE 62. INDIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)

FIGURE 63. JAPAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)

FIGURE 64. JAPAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)

FIGURE 65. JAPAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)

FIGURE 66. JAPAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)

FIGURE 67. SOUTH KOREA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)

FIGURE 68. SOUTH KOREA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)

FIGURE 69. SOUTH KOREA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)

FIGURE 70. SOUTH KOREA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)

FIGURE 71. INDONESIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)

FIGURE 72. INDONESIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)

FIGURE 73. INDONESIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)

FIGURE 74. INDONESIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)

FIGURE 75. SINGAPORE ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)

FIGURE 76. SINGAPORE ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)

FIGURE 77. SINGAPORE ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)

FIGURE 78. SINGAPORE ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)

FIGURE 79. TAIWAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)

FIGURE 80. TAIWAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)

FIGURE 81. TAIWAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)

FIGURE 82. TAIWAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)

FIGURE 83. THAILAND ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)

FIGURE 84. THAILAND ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)

FIGURE 85. THAILAND ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)

FIGURE 86. THAILAND ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)

FIGURE 87. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)

FIGURE 88. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)

FIGURE 89. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)

FIGURE 90. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)

FIGURE 91. ROCHE HOLDING AG: NET SALES, (2021-2023)

FIGURE 92. ROCHE HOLDING AG: PRIMARY MARKET COMPETITORS

FIGURE 93. ABBOTT LABORATORIES: NET SALES, (2021-2023)

FIGURE 94. ABBOTT LABORATORIES: PRIMARY MARKET COMPETITORS

FIGURE 95. THERMO FISHER SCIENTIFIC INC.: NET SALES, (2021-2023)

FIGURE 96. THERMO FISHER SCIENTIFIC INC.: PRIMARY MARKET COMPETITORS

FIGURE 97. DANAHER CORPORATION: NET SALES, (2021-2023)

FIGURE 98. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS

FIGURE 99. BECTON, DICKINSON AND COMPANY: NET SALES, (2021-2023)

FIGURE 100. BECTON, DICKINSON AND COMPANY: PRIMARY MARKET COMPETITORS

FIGURE 101. SIEMENS HEALTHINEERS AG: NET SALES, (2021-2023)

FIGURE 102. SIEMENS HEALTHINEERS AG: PRIMARY MARKET COMPETITORS

FIGURE 103. BIOMéRIEUX SA: NET SALES, (2021-2023)

FIGURE 104. BIOMéRIEUX SA: PRIMARY MARKET COMPETITORS

FIGURE 105. SYSMEX CORPORATION: NET SALES, (2021-2023)

FIGURE 106. SYSMEX CORPORATION: PRIMARY MARKET COMPETITORS

FIGURE 107. QIAGEN N.V.: NET SALES, (2021-2023)

FIGURE 108. QIAGEN N.V.: PRIMARY MARKET COMPETITORS

FIGURE 109. BIO-RAD LABORATORIES, INC.: NET SALES, (2021-2023)

FIGURE 110. BIO-RAD LABORATORIES, INC.: PRIMARY MARKET COMPETITORS

Frequently Asked Questions

The Asia-Pacific in-vitro diagnostics market revenue was valued at USD 27.51 billion in 2023 and is projected to grow at a size of CAGR of 5.4%, reaching up to USD 40.79 billion by 2030.

The key players in the Asia-Pacific in-vitro diagnostics market include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

Germany holds the largest share of the Asia-Pacific in-vitro diagnostics industry, owing to prevalence of chronic diseases.

High costs associated with research, development, and regulatory approval are significant factors restraining the Asia-Pacific IVD market growth.

Introduction of Point-of-Care Testing (POCT) solutions create opportunities for the Asia-Pacific in-vitro diagnostics market in the coming future.

Download Free Sample

Yes, I have read the Privacy Policy

Multi User

$3,975

Single User

$2,975

Enterprise

$5,275

Datapack

$2,975

Our Clients

View All

Features
	Single User	Multi User	Enterprise User	Data Pack
	US $ 2,975	US $ 3,975	US $ 5,275	US $ 2,975
	1 user only	1 user only	Unlimited access within the Organization	1 user only

Free Customization	20 hours	40 hours	>60 hours	NA
Duration Of Free Analyst Support	3 months post purchase	6 months post purchase	12 months post purchase	NA
Direct Access to the Analyst Team Through Calls / Email
Deliverable Format
Deliverable Format
Discount on Your Next Purchase	No Discount	15%	No Discount	No Discount
Permission to Print the Report

Trending Report

Asia-Pacific In-Vitro Diagnostics Market

Asia-Pacific In-Vitro Diagnostics Market Overview

Increasing Chronic Disease Prevalence in Asia-Pacific Drives Significant Market Growth

Technological Advancements Drive the Growth of Market in Asia-Pacific

High Research, Development, and Regulatory Approval Costs Hinder the Market Growth

Introduction of Point-of-Care Testing Solutions in IVD Creates Opportunity

China Dominates the Asia-Pacific In-Vitro Diagnostics Market Share

Singapore to Witness Substantial Growth in the Market

Competitive Landscape

Asia-Pacific In-Vitro Diagnostics Market Key Segments

By Type

By Technique

By Application

By End User

By Country

KEY PLAYERS

Frequently Asked Questions

Download Free Sample

Our Clients

Features

Follow Us On

We Accept

Industries

Trending Report

Asia-Pacific In-Vitro Diagnostics Market

Asia-Pacific In-Vitro Diagnostics Market Overview

Increasing Chronic Disease Prevalence in Asia-Pacific Drives Significant Market Growth

Technological Advancements Drive the Growth of Market in Asia-Pacific

High Research, Development, and Regulatory Approval Costs Hinder the Market Growth

Introduction of Point-of-Care Testing Solutions in IVD Creates Opportunity

China Dominates the Asia-Pacific In-Vitro Diagnostics Market Share

Singapore to Witness Substantial Growth in the Market

Competitive Landscape

Asia-Pacific In-Vitro Diagnostics Market Key Segments

By Type

By Technique

By Application

By End User

By Country

KEY PLAYERS

Frequently Asked Questions

What will be the revenue size of the Asia-Pacific in-vitro diagnostics market?

Which are the key players operating in the Asia-Pacific in-vitro diagnostics market?

Which region holds the largest share of the Asia-Pacific in-vitro diagnostics industry?

What are the restraining factors in the Asia-Pacific IVD market?

What are the growth opportunities in the Asia-Pacific in-vitro diagnostics industry?

Download Free Sample

Our Clients

Related Report

Related Blogs

Technological Advancements Shaping The Minimally Invasive Surgical Systems Market

Revolutionizing Kidney Health: Latest Trends and Advancements in Dialysis Technology

Transforming Healthcare With Patient Monitoring Innovations